Study title: A phase IV multicenter clinical investigation of the safety and efficacy of APAP 1000 mg (total daily dose of 4 grams), ibuprofen 400 mg (total daily dose of 1200 mg), and placebo in the management of the symptoms of primary dysmenorrheaA phase IV multicenter clinical investigation of the safety and efficacy of APAP 1000 mg (total daily dose of 4 grams), ibuprofen 400 mg (total daily dose of 1200 mg), and placebo in the management of the symptoms of primary dysmenorrhea
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Anesthesia and Analgesia [E03] | |||||
Brands: Please see report, Please see report, Please see report, Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: IBUPROFEN AND PSEUDOEPHEDRINE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |